Management of the BRCA Mutation Carrier or High-Risk Patient

Clinics in Plastic Surgery

Volumn 34, Issue 1, 2007, Pages 15-27

  Bordeleau, Louise J ^a,b   Lipa, Joan E ^c,d   Neligan, Peter C ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; EXEMESTANE; PLACEBO; PROGESTERONE; RALOXIFENE; SEX HORMONE; TAMOXIFEN;

BREAST CANCER; BREAST DISEASE; BREAST REDUCTION; BREAST SURGERY; CALCULATION; CANCER PATIENT; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; ENVIRONMENTAL FACTOR; ETHNICITY; FAMILY HISTORY; GENE MUTATION; HEREDITY; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; LIFESTYLE; MASTECTOMY; MODEL; OVARIECTOMY; RACE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SATISFACTION; SUBCUTANEOUS MASTECTOMY;

BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMAPLASTY; MAMMOGRAPHY; MASTECTOMY; MUTATION; OVARIECTOMY; PHYSICAL EXAMINATION; RISK ASSESSMENT;

EID: 33846938558     PISSN: 00941298     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cps.2006.11.010     Document Type: Review

References (112)

1. Fletcher R.H., Fletcher S.W., and Wagner E.H. Rare disease. Clinical epidemiology (1982), Williams & Wilkins, Baltimore (MD) p. 102
2. Vogel V.G. Tools for evaluating a patient's 5 year and lifetime probabilities. Postgrad Med 105 (1999) 49-60
3. Feuer E., Wun L.M., Boring C.C., et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 85 (1993) 890-892
4. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344 (2001) 276-285
5. Willett W.C., Rockhill B., Hankinson S.E., et al. Nongenetic factors in the causation of breast cancer. In: Harris J.R., Lippman M.E., Morrow M., et al. (Eds). Disease of the breast. 3rd edition (2004), Lippincott Williams & Wilkins, Philadelphia 223-276
6. Collaborative Group on Hormonal Factors in Breast Cancer ICEU, Radcliffe Infirmary, Oxford, UK. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347 9017 (1996) 1713-1727
7. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from Women's Health Initiative randomized controlled trial. JAMA 288 3 (2002) 321-333
8. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 14 (2004) 1701-1712
9. National Center for Health Statistics. SEER cancer statistics review, 1973-1995 (1998), National Cancer Institute, Bethesda (MD)
10. Page D.L., Kidd Jr. T.E., DuPont W.E., et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22 (1991) 1232-1239
11. Salvadori B., Bartoli C., Zurrida S., et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer 27 (1991) 35-37
12. Ottesen G.L., Graversen H.P., Blihert-Toft M., et al. Lobular carcinoma in situ of the female breast: the Danish breast cancer cooperative group: short term results of a prospective nationwide study. Am J Surg Pathol 17 (1993) 14-21
13. Claus E.B., Schildkraut J.M., Thompson W.D., et al. The genetic attributable risk of breast and ovarian cancer. Cancer 77 (1996) 2318-2324
14. Ford D., Easton D.F., Stratton M., et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62 (1998) 676-689
15. Martin A.M., and Weber B.L. Genetic and hormonal risk factors in breast cancer. J Natl Cancer Inst 92 (2000) 1126-1135
16. American Society of Clinical Oncology Curriculum. Hereditary breast and ovarian cancer syndromes. In: Offit K, editors. Cancer genetics & cancer predisposition testing. 2nd edition. Alexandria (VA): ASCO Publishing; 2004. p. 6-41.
17. *) 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31 (2002) 55-59
18. *1100delC in New York breast cancer cases and controls. BMC Med Genet 4 (2003) 1
19. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
20. Claus E.B., Risch N., and Thompson W.D. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73 3 (1994) 643-651
21. Tyrer J., Duffy S.W., and Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23 (2004) 1111-1130
22. Amir E., Evans D.G., Shenton A., et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40 (2003) 807-814
23. Berry D.A., Parmigiani G., Sanchez J., et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89 (1997) 227-238
24. Parmigiani G., Berry D.A., and Aguilar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 (1998) 145-158
25. Donald A., Berry D.A., Edwin S., et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20 (2002) 2701-2712
26. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20 (2002) 1480-1490
27. Couch F.J., DeShano M.L., Blackwood M.A., et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336 (1997) 1409-1415
28. Evans D.G., Eccles D.M., Rahman N., et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41 (2004) 474-480
29. Available at: http://acgh.afcri.upenn.edu/cgi-bin/bcm/bcm.pl.
30. Barcenas C.H., Monawar Hosain G.M., et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24 3 (2006) 354-360
31. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 (2003) 2397-2406
32. Oncology ASoC. Statement of the American society of clinical oncology: genetic testing for cancer susceptibility. J Clin Oncol 14 (1996) 1730-1736
33. Carney P.A., Miglioretti D.L., Yankaskas B.C., et al. Individual and combined effects of age, breast density and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (2003) 168-175
34. Brekelmans C.T., Seynaeve C., Bartels C.C., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 19 (2001) 924-930
35. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (2002) 1260-1268
36. Tilanus-Linthorst M., Verhoog I., Obdeijn I.M., et al. A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (2002) 91-95
37. Smith K.L., and Robson M.E. Update on hereditary breast cancer. Curr Oncol Rep 8 (2006) 14-21
38. Tilanus-Linthorst M., Obdeijn I.M., Bartels K.C., et al. First experiences in screening women at high risk for breast cancer with MR imaging. Breast Cancer Res Treat 63 (2000) 53-60
39. Kuhl CK, Schrading S, Leutner CC, et al. Surveillance of high risk women with proven suspected familial (hereditary) breast cancer: first mid-term results of multi-modality clinical screening trial [abstract]. Available at: http://www.asco.org/ac/1,1003,_12-002640-00_18-0023-00_19-00101944,00.asp. Accessed August 9, 2005.
40. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (2004) 427-437
41. Warner E., Plewes D.B., Hill K.A., et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (2004) 1317-1325
42. Lehman C.D., Blume J.D., Weatherall P., et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103 (2005) 1898-1905
43. Leach M.O., Boggis C.R., Dixon A.K., et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365 (2005) 1769-1778
44. Thiery-Vuillemin A., Nguyen T., Pivot X., et al. Molecularly targeted agents: their promise as cancer chemopreventive interventions. Eur J Cancer 41 (2005) 2003-2015
45. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breast cancer in the Royal Marsden hospital tamoxifen randomised chemoprevention trial. Lancet 352 (1998) 98-101
46. Veronesi U., Maisonneuve P., Costa A., et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian tamoxifen prevention study. Lancet 352 (1998) 93-97
47. Veronesi U., Maisonneuve P., Rotmensz N., et al. Italian randomised trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 95 (2003) 160-165
48. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 (2002) 817-824
49. Cuzick J., Powles U., Veronesi J., et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 362 (2003) 296-300
50. Cuzick J. Update on new studies in Europe. [abstract 20]. Eur J Cancer 544 (2002) 38
51. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. JAMA 286 18 (2001) 2251-2256
52. Ettinger B., Black D.M., Mitlak B.H., et al. Multiple outcomes of raloxifene evaluation investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. JAMA 282 (1999) 637-645
53. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA 295 (2006) 2727-2741
54. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
55. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
56. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal woman with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
57. Boccardo F., Rubagotti A., Amoroso D., et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. [abstract 3]. Breast Cancer Res Treat 82 Suppl 1 (2003) S6-S7
58. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
59. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 23 (2005) 1636-1643
60. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (1999) 1475-1479
61. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (2002) 1616-1622
62. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (2002) 1609-1615
63. Eisen A., Lubinski J., Klijn J., et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23 30 (2005) 7491-7496
64. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 2 (1999) 77-84
65. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 21 (2001) 1633-1637
66. Curry P., and Fentiman I.S. Management of women with a family history of breast cancer. Int J Clin Pract 53 (1999) 192-196
67. Kasprzak L., Mesurolle B., Tremblay F., et al. Invasive breast cancer following bilateral subcutaneous mastectomy in a BRCA2 mutation carrier: a case report and review of the literature. World J Surg Oncol 3 (2005) 52
68. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22 6 (2004) 1055-1062
69. Ziegler L.D., and Kroll S.S. Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14 5 (1991) 451-454
70. Baasch M., Nielsen S.F., Engholm G., et al. Breast cancer incidence subsequent to surgical reduction of the female breast. Br J Cancer 73 7 (1996) 961-963
71. Brinton L.A., Persson I., Boice Jr. J.D., et al. Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer 91 3 (2001) 478-483
72. Tarone R.E., Lipworth L., Young V.L., et al. Breast reduction surgery and breast cancer risk: does reduction mammaplasty have a role in primary prevention strategies for women at high risk of breast cancer?. Plast Reconstr Surg 113 7 (2004) 2104-2110 [discussion: 2111-2]
73. Orgill D.P., Iglehart J.D., and Gelman R. Discussion: breast reduction surgery and breast cancer risk: does reduction mammaplasty have a role in primary prevention strategies for women at high risk of breast cancer?. Plast Reconstr Surg 113 7 (2004) 2111-2112
74. Eldar S., Meguid M.M., and Beatty J.D. Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 148 (1984) 692-693
75. Pennisi V.R., and Capozzi A. Subcutaneous mastectomy data: a final statistical analysis of 1500 patients. Aesthetic Plast Surg 13 1 (1989) 15-21
76. Slade C.L. Subcutaneous mastectomy: acute complications and long-term follow-up. Plast Reconstr Surg 73 1 (1984) 84-90
77. Goodnight Jr. J.E., Quagliana J.M., and Morton D.L. Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 26 (1984) 198-201
78. Jameson M.B., Roberts E., Nixon J., et al. Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. Clin Oncol 9 (1997) 119-121
79. Cheung K.L., Blamey R.W., Robertson J.F., et al. Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ. Eur J Surg Oncol 23 4 (1997) 343-347
80. Metcalfe K.A., Semple J.L., and Narod S.A. Time to reconsider subcutaneous mastectomy for breast-cancer prevention?. Lancet Oncol 6 6 (2005) 431-434
81. Spear S.L., Carter M.E., and Schwarz K. Prophylactic mastectomy: indications, options, and reconstructive alternatives. Plast Reconstr Surg 115 3 (2005) 891-909
82. Schrag D., Kuntz K.M., Garber J.E., et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336 20 (1997) 1465-1471
83. Kollias J., Ellis I.O., Elston C.W., et al. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25 6 (1999) 584-589
84. Verhoog L.C., Brekelmans C.T., Seynaeve C., et al. Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83 (2000) 584-589
85. Schrag D., Kuntz K.M., Garber J.E., et al. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283 5 (2000) 617-624
86. Shahedi K., Emanuelsson M., Wiklund F., et al. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 106 6 (2006) 1237-1242
87. Bresser P.J., Seynaeve C., Van Gool A.R., et al. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 117 6 (2006) 1675-1682 [discussion: 1683-4]
88. Payne D.K., Biggs C., Tran K.N., et al. Women's regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 7 2 (2000) 150-154
89. Hopwood P., Lee A., Shenton A., et al. Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. Psychooncology 9 6 (2000) 462-472
90. Frost M.H., Schaid D.J., Sellers T.A., et al. Long term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 284 (2000) 319
91. Spear S.L., Pennanen M., Barter J., et al. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2-positive patient. Plast Reconstr Surg 103 2 (1999) 548-553 [discussion: 554-5]
92. Morris R.J., Koshy C.E., and Zambacos G.J. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2negative patient. Plast Reconstr Surg 105 1 (2000) 473
93. Howley B, Lipa J, Hauspy J, et al. Prophylactic surgery in BRCA gene mutation carriers: should we combine mastectomy, autogenous reconstruction and ovarian surgery? [abstract]. Paper Presented at the Canadian Society of Plastic Surgeons. Quebec City, QC, Canada, June 16, 2006.
94. Muller C.Y., Coleman R.L., and Adams Jr. W.P. Laparoscopy in patients following transverse rectus abdominis myocutaneous flap reconstruction. Obstet Gynecol 96 1 (2000) 132-135
95. Awtrey C.S., Abu-Rustum N.R., Disa J.J., et al. Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery. Gynecol Oncol 99 3 (2005) 720-725
96. Lipa JE, Neligan PC. Algorithm for the transfer of abdominal tissue for breast reconstruction in cases of previous abdominal surgery [abstract]. Paper Presented at the GAM Canada. Hamilton, ON, Canada, June 2, 2004.
97. Duggan C., Marriott K., Edwards R., et al. Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer. J Clin Oncol 21 19 (2003) 3588-3593
98. Shaikh N., LaTrenta G., Swistel A., et al. Detection of recurrent breast cancer after TRAM flap reconstruction. Ann Plast Surg 47 6 (2001) 602-607
99. Helvie M.A., Wilson T.E., Roubidoux M.A., et al. Mammographic appearance of recurrent breast carcinoma in six patients with TRAM flap breast reconstructions. Radiology 209 3 (1998) 711-715
100. Mund D.F., Wolfson P., Gorczyca D.P., et al. Mammographically detected recurrent nonpalpable carcinoma developing in a transverse rectus abdominus myocutaneous flap. A case report. Cancer 74 10 (1994) 2804-2807
101. Helvie M.A., Bailey J.E., Roubidoux M.A., et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 224 1 (2002) 211-216
102. Devon R.K., Rosen M.A., Mies C., et al. Breast reconstruction with a transverse rectus abdominis myocutaneous flap: spectrum of normal and abnormal MR imaging findings. Radiographics 24 5 (2004) 1287-1299
103. Kang B.J., Jung J.I., Park C., et al. Breast MRI findings after modified radical mastectomy and transverse rectus abdominis myocutaneous flap in patients with breast cancer. J Magn Reson Imaging 21 6 (2005) 784-791
104. Eidelman Y., Liebling R.W., Buchbinder S., et al. Mammography in the evaluation of masses in breasts reconstructed with TRAM flaps. Ann Plast Surg 41 3 (1998) 229-233
105. Azavedo E., and Bone B. Imaging breasts with silicone implants. Eur Radiol 9 2 (1999) 349-355
106. Bone B., Aspelin P., Isberg B., et al. Contrast-enhanced MR imaging of the breast in patients with breast implants after cancer surgery. Acta Radiol 36 2 (1995) 111-116
107. Ahn C.Y., Shaw W.W., Narayanan K., et al. Definitive diagnosis of breast implant rupture using magnetic resonance imaging. Plast Reconstr Surg 92 4 (1993) 681-691
108. Brem R.F., Tempany C.M., and Zerhouni E.A. MR detection of breast implant rupture. J Comput Assist Tomogr 16 1 (1992) 157-159
109. Brown S.L., Silverman B.G., and Berg W.A. Rupture of silicone-gel breast implants: causes, sequelae, and diagnosis. Lancet 350 9090 (1997) 1531-1537
110. Lindbichler F., Hoflehner H., Schmidt F., et al. Comparison of mammographic image quality in various methods of reconstructive breast surgery. Eur Radiol 6 6 (1996) 925-928
111. Pickford M.A., and Webster M.H. Implant rupture by mammography. Br J Plast Surg 47 7 (1994) 512
112. Brown S.L., Todd J.F., and Luu H.M. Breast implant adverse events during mammography: reports to the Food and Drug Administration. J Womens Health (Larchmt) 13 4 (2004) 371-378 [discussion: 379-80]